Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer

Conclusions: Additional outreach to patients treated with vandetanib had no impact on the rate or severity of AEs compared to the standard AE monitoring schedule. AEs were consistent with the known safety profile of vandetanib.Eur Thyroid J 2016;5:187-194
Source: European Thyroid Journal - Category: Endocrinology Source Type: research